TZU-HAO CHENG(鄭子豪)

PERSONAL INFORMATION

Gender: Male Date of birth: February 27, 1966 Place of birth: Taiwan

Phone: (886)-2-28267331 Fax: (886)-2-28264843 Email:

EDUCATION

2000Ph.D. Cellular and MolecularPharmacology/

Rutgers University/UMDNJ, New Jersey, USA

1991M.S.Biochemistry/

National Yang-Ming University (NYMU), Taipei, Taiwan

1988B.S.Chemical Engineering/

National Tsing-Hua University, Hsinchu, Taiwan

POSITIONS & EMPLOYMENT

2016Director Institute of Biochemistry and Molecular Biology, NYMU

2015Acting DirectorInstitute of Biochemistry and Molecular Biology, NYMU

2012 ProfessorInstitute of Biochemistry and Molecular Biology, NYMU

2010Associate ProfessorInstitute of Biochemistry and Molecular Biology, NYMU

2003 Assistant ProfessorInstitute of Biochemistry and Molecular Biology, NYMU

2000Post-doctoral FellowGenetics Department, Stanford University

PUBLICATIONS

CR Liu and TH Cheng*. (2015). Allele-selective Suppression of Mutant Genes in Polyglutamine Diseases. Journal of neurogenetics29(2-3): 41-49.

HM Cheng, Y Chern, IH Chen, CR Liu, SH Li,S Chun, F Rigo,CF Bennett, N Deng, Y Feng,CS Lin, YT Yan*, SN Cohen*, and TH Cheng*. (2015). Effects on Murine Behavior and Lifespan by Selectively Decreasing Expression of Mutant Huntingtin Allele by Supt4h knockdown.PLoS Genetics11, e1005043.

HS Hsu, MH Lin, YH Jang, TT Kuo, CC Liu, andTH Cheng*. (2015). The4E-BP1/eIF4E ratio is a determinant for rapamycin response in esophageal cancer cells. Journal of Thoracic and Cardiovascular Surgery 149, 378-385.

YS Lin, YJ Chen, SN Cohen, andTH Cheng*. (2013). Identification of TSG101 functional domains and p21 loci required for TSG101-mediated p21 gene regulation. PLoSOne 8, e79674.

YS Lin, TH Cheng, CP Chang, HM Chen, and Y Chern*.(2013). Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease.Biochim Biophys Acta. 1832, 742-753.

CR Liu, CR Chang, Y Chern, TH Wang, WC Hsieh, WC Shen, CY Chang, IC Chu, N Deng, SN Cohen*, and TH Cheng*. (2012). Spt4 is Selectively Required for Transcription of Extended Trinucleotide Repeats.Cell 148, 690-701.

YT Lin, Y Chern, CK Shen, HL Wen, YC Chang, H Li, TH Cheng, and HM Hsieh-Li*.(2011). Human Mesenchymal Stem Cells Prolong Survival and Ameliorate Motor Deficit through Trophic Support in Huntington’s Disease Mouse Models. PLoS One 6, e22924.

HS Hsu*, HW Chen, CL Kao, ML Wu, Anna FY Li, and TH Cheng*. (2011). MDM2 isoverexpressed and regulated by the eukaryotic translation initiation factor 4E(eIF4E) in human squamous cell carcinoma of esophagus.Annals of Surgical Oncology18, 1469-1477.

YW Liu, YW Su, WK Ong, TH Cheng*, and YC Tsai*. (2011). Oral administration of Lactobacillus plantarum K68 ameliorates DSS-induced ulcerative colitis in BALB/c mice via the anti-inflammatory and immunomodulatory activities.International Immunopharmacology11, 2159-66.

V Ghukasyan, CC Hsu, CR Liu, FJ Kao* and TH Cheng*. (2010). Fluorescencelifetime dynamics of eGFP in protein aggregates with expanded polyQ.Journal of Biomedical Optics 15, 016008.

CL Kao, HS Hsu, HW Chen, and TH Cheng*. (2009). Rapamycin increases thep53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition ofmdm2in cancer cells.Cancer Letters 286, 250-259.

TH Cheng, PK Hsu, Anna FY Li, IC Hung, MH Huang, and HS Hsu*. (2009).Correlation of p53, MDM2, and p14ARF protein expression in Human EsophagealSquamous Cell Carcinoma.Journal of Cancer Research and Clinical Oncology 135, 1577-1582.

HH Chua, HH Lee, SS Chang, CC Lu, TH Yeh, TY Hsu, TH Cheng, JT Cheng, MRChen, and CH Tsai*. (2007). Role of TSG101 in Epstein-Barr viral late genetranscription.Journal of Virology 81, 2459-2471.

TH Chengand SN Cohen*. (2007). Human MDM2 isoforms translated differentiallyon constitutive versus p53-regulated transcripts have distinct functions in thep53/MDM2 and TSG101/MDM2 feedback control loops.Molecular and Cellular Biology 27, 111-119.

SH Chao, TH Cheng, CY Shaw, MH Lee, YH Hsu, and YC Tsai*. (2006).Characterization of a Novel PepF-Like Oligopeptidase Secreted by Bacillusamyloliquefaciens 23-7A.Applied and Environmental Microbiology 72, 23-27.

YC Li, TH Cheng, and MR Gartenberg*. (2001). Establishment oftranscriptional silencing in the absence of DNA replication.Science 291, 650-653.

TH Chengand MR Gartenberg*. (2000). Yeast silent chromatin is adynamic structure that requires silencers continuously.Genes and Development 14, 452-463.

TH Cheng, CR Chang, P Joy, S Yablok, and MRGartenberg*. (2000). Controlling gene expression in yeast by inducible site-specificrecombination.Nucleic Acids Research e28.

A Ansari, TH Cheng, MR Gartenberg*. (1999). Isolation of chromatinrings from yeast employing site-specific recombination in vivo.Methods 17, 104-111.

TH Cheng, YC Li, and MR Gartenberg*. (1998). Persistence of analternate chromatin structure at silenced loci in the absence of silencers.Proc Natl Acad Sci U S A 95, 5521-5526.

PATENTS

  1. Recombinant protein and method of screening for agents modulate polypeptide aggregation (Inventors: TH Chengand CR Liu)

USA patent, Patent Number: US 7,375,190 B2

ROC patent, Patent Number: I 327168

  1. Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same(Inventors: TH Cheng, CR Liu, TH Wang, and SN Cohen)

USA patents, Patent Number: US 8,569,254 B2; US 9,226,935 B2

ROC patent, Patent Number: I 430812

Japan patent, Patent Number: 5769084

EUpatent, Patent Number: 2463372

  1. Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes(Inventors: TH Cheng, CR Liu, TH Wang, and SN Cohen)

USA patent, Patent Number: US 9,211,303 B2